Reportedly, state governors to work with the U.S. Food and Drug Administration will be extending the shelf life of Johnson & Johnson’s (JNJ) COVID-19 vaccine after White House orders, as millions of doses remain unused nationwide and are near to expiry.
“I would encourage every governor who has doses that they worry may be expiring to work with the FDA directly on the proper storage procedures as they continue to examine processes that will allow them to potentially last longer,” stated White House COVID-19 Advisor Andy Slavitt said on a Tuesday press call.
Safety concerns regarding the J&J’s one shot Covid-19 vaccine and fading demand for vaccinations have left nearly half of the 21 million doses J&J has produced for the United States sitting unused.
Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare-focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services. To learn more about Johnson & Johnson (JNJ) and to continue to track its progress visit the Vista Partners Johnson & Johnson Coverage Page.
If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based biotech firm’s work towards finding therapeutic treatments for Breast Cancer and the Coronavirus.
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive! Please join us at Vista Partners and receive our FREE email updates throughout the week and view our exclusive content and research.